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Abstract 
We previously identified a systemic metabolic defect associated with early 
weight loss in patients with Huntington disease (HD) suggesting a lack of 
substrates for the Krebs cycle. Dietary anaplerotic therapy with triheptanoin is 
used in clinical trials to promote energy production in patients with peripheral 
and brain Krebs cycle deficit, as its metabolites – C5 ketone bodies – cross 
the blood brain barrier. We conducted a short-term clinical trial in six HD 
patients (UHDRS= 33 13, 15-49) to monitor the tolerability of triheptanoin. 
We also assessed peripheral markers of short-term efficacy that were shown 
to be altered in early stages of HD, i.e. low serum IGF1 and 31P-NMR 
spectroscopy (NMRS) in muscle. At baseline, 31P-NMRS displayed two 
patients with end-exercise muscle acidosis despite a low work output. On day 
2, the introduction of triheptanoin was well tolerated in all patients, and in 
particular, there was no evidence of mitochondrial overload from triheptanoin-
derived metabolites. After 4 days of triheptanoin-enriched diet, muscle pH 
regulation was normalized in the two patients with pre-treatment metabolic 
abnormalities. A significant increase of serum IGF1 was also observed in all 
patients (205 ng/ml 60 versus 246 ng/ml 68, p=0.010). This study provides 
a rationale for extending our anaplerotic approach with triheptanoin in HD. 
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Introduction 
Huntington disease (HD) is an inherited severely disabling disorder without 
curative or preventive treatment. We showed that early weight loss in HD is 
associated with a systemic metabolic defect, and that branched chain amino 
acids (BCAA) levels can be used as a biomarker, indicative of disease onset 
and early progression.1 Levels of IGF1, which is regulated by BCAA, were 
also significantly lower in the HD group.1 The decrease in plasma BCAA 
observed in our HD group suggested the activation of a compensatory 
mechanism to provide energy substrates to the Krebs cycle, as described in 
cachexia-producing illnesses.2 Likewise, dietary compounds such as 
triheptanoin have been used in human therapeutic trials for their ability to refill 
the pools of intermediates of the Krebs cycle, a key energetic process called 
anaplerosis.3 Because of additional evidence for triheptanoin metabolites to 
cross the blood brain barrier,4 anaplerotic therapies represent promising 
molecules for reversing the energy deficit observed in both the brain and the 
periphery in HD patients. Based on the hypothesis that there is a need for 
Krebs cycle energy substrates in HD, we conducted a pilot study using a 
dietary anaplerotic approach to assess safety and short-term metabolic 
correction. 
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Methods 
Study design 
We included six HD patients with abnormal CAG repeats expansions (mean= 
46 3) in the HTT gene with a mild to moderate disease, measured by the 
clinical scale UHDRS (Unified Huntington Disease Rating Scale) of 33 13 
(Table 1). All participants were enrolled in a clinical protocol promoted by 
INSERM (COS 07-26, http://bir.inserm.fr), and approved by the local ethics 
committee. Written informed consent was obtained for all participants. 
 
On the screening day – approximately one month prior to the therapeutic trial 
– motor dysfunction was evaluated with the UHDRS, and each HD participant 
underwent 31P-NMRS testing in muscle. The six HD patients were asked to fill 
an opened-ended questionnaire during three consecutive days so that the 
dietician could determine caloric intake and devise daily menus ensuring that 
the triheptanoin oil provide 40% of an isocaloric diet, as previously 
established.3,4 At day 1, the six HD participants were hospitalized and height 
and weight were recorded to calculate the body mass index (BMI). Blood and 
urine samples were collected after an overnight fast for standard analyses as 
well as plasma acylcarnitines, amino acids and ketone bodies, serum IGF1 
and urine organic acids as described.4 At day 2, HD patients ingested the first 
doses of triheptanoin (1g/Kg/day divided in four meals). Repeated blood 
samples were collected before and, sequentially, after the first meal (30, 60, 
90, 120 and 180 minutes after triheptanoin ingestion) for assessment of 
acylcarnitines profile, amino acids and ketone bodies. Urine samples were 
collected before and after the first ingestion of triheptanoin (90 and 180 
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minutes) for analyses of organic acids. During the next 3 days, HD 
participants kept consuming an isocaloric diet enriched with triheptanoin 
(1g/Kg/day). At day 5, standard analyses were repeated fasting, as well as 
plasma acylcarnitines, amino acids and ketone bodies, serum IGF1 and urine 
organic acids. UHDRS scoring was performed and muscle 31P-NMRS was 
repeated. In view of the low risks to subjects participating in this protocol, 
continuous and close monitoring by the Principal Investigator was done on an 
ongoing basis during the days the patients were taking triheptanoin – almost 
all triheptanoin-derived metabolites being utilized 3 to 4 hours after its 
administration.4 
 
31P-NMR spectroscopy in muscle 
NMR was carried out as described.5 Data were analyzed semi-automatically 
to provide: perfusion time-course, PCr rephosphorylation time constant (τPCr) 
and end-exercise acidosis level (pH). Intensity of exercise (W/S) was 
determined by correcting work output (W, in Joules) developed during 
exercise to calf muscle area section (S, in cm2). 
 
Statistics 
The data are expressed as the mean ± standard error of the mean. Paired t-
tests (SPSS) were used to compare the values of plasma acylcarnitines, 
serum IGF1 and UHDRS before and after triheptanoin. 
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Results 
Patients’ BMI ranged from 19 to 25. There was no correlation between CAG 
repeats and metabolic measurement at baseline, except for an inverse 
correlation with plasma glutamine (p<0.001). All patients tolerated the 
treatment well and no adverse event was monitored during the trial and 
beyond. As a result of feeding triheptanoin, urinary excretion of derivatives of 
heptanoate oxidation were detected – pimelate, 6-hydroxyheptanoate, 3-
hydroxypentanoate (BHP), 3-ketopentanoate (BKP), 3-hydroxypropionate, 
and methylcitrate – but there was no evidence of mitochondrial overload from 
triheptanoin-derived metabolites. Among plasma triheptanoin-derived 
metabolites, there was no substantial increase in either pentanoylcarnitine 
(C5) or heptanoylcarnitine (C7) (data not shown) but propionylcarnitine (C3) 
increased significantly in all patients (Table 1) indicating complete beta-
oxidation of heptanoate to propionyl-CoA. Substantial increases of C5 ketone 
bodies were observed after meal and triheptanoin administration (data not 
shown), with BHP to BKP ratios between 2.1 to 2.8. Plasma BCAA initially 
decreased after triheptanoin administration and then returned to their baseline 
levels on day 5 (data not shown). There was no significant change in the 
UHDRS scores before and after triheptanoin (Table 1). There was no 
correlation either between CAG repeats and the levels of triheptanoin 
metabolites (data not shown).  
 
During plantar flexion dynamic 31P-NMRS, all HD patients presented with a 
work output about two to four fold lower (Supplementary Table) than what is 
seen in healthy individuals – W/S= 34.96 J/cm2 ±16.35, n=7. Measurements 
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of intramuscular pH showed that two patients (P5 and P6) presented with 
end-exercise muscle acidosis – pH at 6.72 and 6.84, Figure 1 – despite even 
lower exercise intensity compared to the four other patients – W/S at 11.44 
J/cm2 and 9.40 J/cm2 respectively, Supplementary Table. Creatine 
rephosphorylation time constant was also increased in these two patients – 
tPCr respectively of 63.1 and 52.5s – but turned out to be normal when 
corrected for pH.6 Of note, patient 5 had the lower BMI (i.e. 19) whereas 
patient 6 had the higher UHDRS score (i.e. 49). 
 
Remarkably, after 4 days of triheptanoin-enriched diet, we observed a 
correction of end-exercise muscle acidosis – pH at 6.97 and 6.98, Figure 1 – 
in the two patients with pre-treatment metabolic abnormalities (P5 and P6). 
This was associated with different hyperemic responses after treatment with 
an earlier return to basal level of perfusion for patient 5 (Figure 2) and the 
occurrence of a distinct peak of functional hyperemia from the 3rd minute of 
recovery for patient 6 (Figure 2). In addition, we observed a significant 
increase of serum IGF1 in all HD patients (Table 1).  
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Discussion 
Based on our observation of a hypercatabolic profile early in HD, our short-
term study aimed at directly identifying an energy deficit followed by a 
therapeutic intervention to improve peripheral energy metabolism in HD 
patients. Our anaplerotic approach using dietary triheptanoin was well 
tolerated in all HD patients, both clinically and biochemically. Of note, the 
levels of plasma BCAA decreased temporarily after the initiation of 
triheptanoin before returning to their baseline levels, likely reflecting the  
reversible inhibition of branched chain -ketoacid dehydrogenase kinase by 
medium chain fatty acids.7 Furthermore, we analyzed markers of peripheral 
energy metabolism that were shown to be altered in early stages of HD, i.e. 
low serum IGF11 or delayed phosphocreatine recovery (tPCr) after exercise 
measured by 31P-NMR spectroscopy in muscle.8,9 Although 31P-NMR 
spectroscopy can lack sensitivity to detect mitochondrial dysfunction,10 the 
most noticeable finding from our study was that two patients developed 
muscle acidosis at baseline while performing a low intensity exercise. Their 
end-exercise pH corresponded to W/S ratios three-fold higher than in normal 
subjects (data not shown). These two patients also had longer tPCrs but, 
when corrected for pH, tPCrs appeared to be unaltered.6 This observation 
differs from previous observations although end-exercise pH was either not 
reported,8 or unaltered in the HD group.9 Of note, our anaplerotic approach 
with triheptanoin led to a normalization of end-exercise muscle acidosis in the 
two patients with pre-treatment abnormalities. NMR measurements of muscle 
perfusion also suggested an effect of triheptanoin on hyperemic responses to 
exercise. Moreover, the improvement of peripheral energy metabolism in our 
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study is supported by the significant increase of serum IGF1 in all HD 
patients. IGF1 impacts mutant huntingtin by promoting its phosphorylation. 
Phosphorylation inhibits mutant huntingtin toxicity by restoring its transport 
function.11,12 Therefore, the increase of IGF1 following treatment with 
triheptanoin may exert direct beneficial effects by restoring huntingtin function 
and/or blocking huntingtin toxicity in peripheral organs and possibly in the 
brain. It is not clear how triheptanoin mediates IGF1 levels, especially since 
triheptanoin did not increase the levels of BCAA – known to regulate IGF1. 
Ketone bodies cross the blood brain barrier and ketogenic diet was shown to 
modulate IGF1 metabolism in the rat brain.13 Likewise, it would be interesting 
to assess in vitro whether the ketone bodies derived from triheptanoin – i.e. 
BHP and BKP – can modulate IGF1 levels and huntingtin phosphorylation in 
primary cultures of striatal neurons.  
 
In addition to the prominent role of brain energy deficit in the pathophysiology 
of HD,14,15 there are several lines of evidence for a more systemic energy 
deficit. Our findings of hypercatabolism in HD1 were indeed recently confirmed 
in both clinical 16,17 and preclinical studies.18,19 Our data emphasize that 31P-
NMRS may provide relevant biomarkers of peripheral energy metabolism in 
HD. This study also provides a rationale for extending our anaplerotic 
approach with triheptanoin in HD. A double-blind placebo-controlled trial with 
clinical outcome measurements is planned in order to confirm the potential 
benefit of anaplerotic therapies to improve, or even reverse, the energy deficit 
both in the periphery and the brain of HD patients and presymptomatic 
individuals.  
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Table 1: Clinical characteristics of the six HD patients, as well as UHDRS, plasma propionylcarnitine (C3-carnitine) and serum 
IGF1 levels, before and after triheptanoin. Paired t-tests were used to compare the values before and after triheptanoin and 
significant changes are indicated with p values. * Pathological repeats size. 
 
 
Sex CAG* 
Age at 
onset 
(years) 
Age at 
examination 
(years) 
UHDRS Plasma C3-carnitine ( mol/l) Serum IGF1 (ng/ml) 
Pre-
treatment 
Post-
treatment 
Pre-
treatment 
Post-
treatment 
p Pre-
treatment 
Post-
treatment 
p 
P1 F 46 49 51 39 43 0.17 0.52  115 136  
P2 M 43 45 60 30 31 0.13 0.29  196 268  
P3 F 51 30 34 43 38 1.16 2.85  282 343  
P4 F 45 45 50 20 15 0.94 1.85  238 254  
P5 F 43 40 48 15 9 0.52 1.78  236 246  
P6 F 50 33 41 49 45 0.88 2.05  165 218  
Total  46 ±3 40 ±7 47 ±9 33 ±13 30 ±15 0.63  0.43 1.56  0.97 0.011 205  60 246  68 0.010 
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Figure legends 
 
Figure 1: End-exercise pH before (1) and after (2) triheptanoin in 6 patients 
with Huntington disease (P1-P6). We observed normalization of the pH in the 
two patients (P5 and P6) with pre-treatment metabolic abnormalities. 
 
Figure 2: Perfusion kinetics during exercise recovery before and after 
treatment in patients 5 and 6.  The global hyperemic response was improved 
after treatment: more regular and rapid return to basal level for patient 5 (left 
panel) and distinction of a peak of hyperemia before reaching basal level of 
perfusion for patient 6 (right panel). 
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